LB Pharmaceuticals Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for LB Pharmaceuticals Inc (LBRX) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022
Period EndingDec 2024Dec 2023Dec 2022
Operating Activities
Net Income-63.10-6.28-14.35
Depreciation & Amortization0.090.000.00
Stock Based Compensation3.160.300.43
Change in Working Capital3.31-1.310.09
Change in Accounts Receivable0.110.000.00
Change in Accounts Payable0.001.100.13
Change in Other Working Capital3.203.92-0.05
Other Operating Activities3.493.929.46
Net Cash from Operating Activities-53.05-12.09-2.73
Investing Activities
Capital Expenditures-0.77-0.030.00
Purchases of Investments-29.75-33.990.12
Sales/Maturities of Investments53.756.000.12
Net Cash from Investing Activities23.23-28.010.12
Financing Activities
Common Stock Issued0.000.000.00
Other Financing Activities38.32-2.05-2.95
Net Cash from Financing Activities38.3233.6822.96
Summary
Net Change in Cash8.50-6.4320.36
Cash at Beginning of Period14.9821.401.05
Cash at End of Period23.4814.9821.40
Free Cash Flow-53.82-12.12-2.73
Supplemental Disclosures
Interest Paid0.001.980.00
Income Taxes Paid0.000.000.00